SCHEMBL11606286

SCHEMBL11606286

Cc1cccc2c([C]=O)cccc12

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 5/20 0.59
CYP2A6 P11509 3/20 0.59
ALDH1A1 P00352 3/20 0.44
TSHR P16473 2/20 0.38
CYP3A4 P08684 1/20 0.35
HPGD P15428 1/20 0.35
HSD17B10 Q99714 1/20 0.35
MAPT P10636 3/20 0.34
CES1 P23141 2/20 0.34
HIF1A Q16665 2/20 0.34
EPAS1 Q99814 2/20 0.34
CES2 O00748 1/20 0.34
KDM1A O60341 1/20 0.34
EED O75530 1/20 0.34
POLB P06746 1/20 0.34
PTPN6 P29350 1/20 0.34
BLM P54132 1/20 0.34
PTPN11 Q06124 1/20 0.34
SUZ12 Q15022 1/20 0.34
EZH2 Q15910 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3240672 0.86 CYP1A2 (0.59) CYP1A2CYP2A6ALDH1A1TSHRCYP3A4
SCHEMBL1227243 0.85 CA1 (0.38) CYP1A2CYP2A6ALDH1A1TSHRCYP3A4
SCHEMBL10628135 0.78 CYP1A2 (0.42) CYP1A2CYP2A6ALDH1A1TSHRCYP3A4
SCHEMBL9824699 0.78 CYP1A2 (0.68) CYP1A2CYP2A6ALDH1A1TSHRHPGD
SCHEMBL29712917 0.78 CYP1A2 (0.68) CYP1A2CYP2A6ALDH1A1TSHRHPGD
SCHEMBL879078 0.77 TSHR (0.60) CYP1A2CYP2A6ALDH1A1TSHRMAPT
SCHEMBL424167 0.77 CYP1A2 (1.00) CYP1A2CYP2A6ALDH1A1TSHRCYP3A4
SCHEMBL29463284 0.77 CYP1A2 (1.00) CYP1A2CYP2A6ALDH1A1TSHRCYP3A4
SCHEMBL1312250 0.76 CYP3A4 (0.43) CYP1A2CYP2A6ALDH1A1TSHRCYP3A4
SCHEMBL49876 0.75

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230270763-A1 METHOD OF TREATING CORONOVIRUS INFECTIONS WITH CANNABINOIDS AND DERIVATIVES PASCAL BIOSCIENCES INC (CA) 2023-08-31 US disclosed
WO-2022006498-A1 METHOD OF TREATING CORONAVIRUS INFECTIONS WITH CANNABINOIDS AND DERIVATIVES PASCAL BIOSCIENCES INC. (CA) 2022-01-06 WO disclosed
US-20210038559-A1 CANNABINOIDS AND DERIVATIVES FOR PROMOTING IMMUNOGENICITY OF TUMOR AND INFECTED CELLS PASCAL BIOSCIENCES INC. (CA) 2021-02-11 US disclosed
EP-3743061-A1 CANNABINOIDS AND DERIVATIVES FOR PROMOTING IMMUNOGENICITY OF TUMOR AND INFECTED CELLS Pascal Biosciences Inc. (CA) 2020-12-02 EP disclosed
WO-2019144126-A1 CANNABINOIDS AND DERIVATIVES FOR PROMOTING IMMUNOGENICITY OF TUMOR AND INFECTED CELLS PASCAL BIOSCIENCES INC. (CA) 2019-07-25 WO disclosed
US-4084049-A CEPHALOSPORIN ANTIBIOTICS FUJISAWA PHARMACEUTICAL CO., LTD. (JA) 1978-04-11 US disclosed
US-3984397-A CYCLIZATION FUJISAWA PHARMACEUTICAL CO., LTD. (JA) 1976-10-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230270763-A1 METHOD OF TREATING CORONOVIRUS INFECTIONS WITH CANNABINOIDS AND DERIVATIVES CNR1, CNR2, SARS1 CYP1A2 960/4885CYP2A6 159/4885ALDH1A1 3300/4885
US-20210038559-A1 CANNABINOIDS AND DERIVATIVES FOR PROMOTING IMMUNOGENICITY OF TUMOR AND INFECTED CELLS CNR1, CNR2, CD74 CYP1A2 2728/4885CYP2A6 847/4885ALDH1A1 4140/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.